BSD Medical Debuts University of Utah’s Huntsman Cancer Institute as U.S. Teaching Center for MicroThermX® Microwave Ablation System
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported that University of Utah’s Huntsman Cancer Institute (HCI) has been established as a teaching center and Center of Excellence in the U.S. for the MicroThermX® Microwave Ablation System (MicroThermX). HCI will provide training on the microwave ablation treatments using the MicroThermX for physicians throughout the U.S. As part of the training, physicians will be able to observe microwave ablation treatments using the MicroThermX at HCI. HCI physicians will also provide consulting services and serve as a resource center for information on microwave ablation treatments using the MicroThermX.
“We are excited to have this prestigious cancer center agree to serve as a teaching center and a Center of Excellence for the MicroThermX”
"We are excited to have this prestigious cancer center agree to serve as a teaching center and a Center of Excellence for the MicroThermX," said Harold Wolcott, President of BSD Medical. "Setting up teaching centers throughout the U.S. is part of BSD's comprehensive marketing strategy to build the network of physicians using the MicroThermX and thus increase BSD's market share. HCI will serve as a comprehensive resource and training center for academic and clinical training on microwave ablation treatments using the MicroThermX for both current and future physicians and researchers."
About Huntsman Cancer Institute
Huntsman Cancer Institute (HCI) is part of the University of Utah Health Care system. HCI is a National Cancer Institute (NCI)-Designated Cancer Center, which means it meets the highest standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer. HCI serves thousands of cancer patients throughout the Intermountain West every year and provides academic and clinical training for future physicians and researchers. Patients are referred to HCI from a broad, multistate region. HCI ensures that every person receives excellent cancer care and is able to benefit from the latest advances in cancer diagnosis, treatment, and prevention strategies through participation in clinical trials.
About the MicroThermX Microwave Ablation System
The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by MicroThermX BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream.
The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts, including statements relating to our 2014 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.